Adjuvant Tislelizumab plus chemotherapy after post-operative pelvic chemoradiation in high risk endometrial cancer.

This clinical trial seeks to improve outcomes for patients with high-risk endometrial cancer, who have a significant risk of relapse after standard post-operative treatment with chemotherapy and radiotherapy. The trial will find out if relapse rates can be lowered by adding immunotherapy to current standard therapy. Patients will be randomly assigned to receive the new treatment combination or existing standard treatment, then followed up

to see if outcomes are improved and what side-effects occur.

See ANZCTR for full trial details >


Trial Summary:

To determine if patient outcomes can be improved by adding Tislelizumab to standard adjuvant chemotherapy after post-operative pelvic chemoradiation for high-risk endometrial cancer.

Supported By:

 Supported By: Medical Research Future Fund 2019 RCRDUN, BeiGene


Patients with high-risk endometrial cancer, FIGO 2018 Stage III or IVA endometrial cancer with endometroid histology or FIGO 2018 Stage II-IVA endometrial cancer with serious, clear cell or carcinosarcoma histology. The patient has completed prior surgical treatment with total hysterectomy and bilateral salpingo-oophorectomy +/- lymph node evaluation and planned for adjuvant therapy but has not received prior chemotherapy nor prior pelvic radiation therapy.

Registration ID:




Australian Lead Group:




Activation Date:

4th March 2022


Prof Linda Mileshkin and Dr Yeh Chen Lee